AMRI Completes Strategic European Acquisition
News Mar 02, 2006
On January 30, AMRI announced the signing of a stock purchase agreement to acquire ComGenex. The completed acquisition provides AMRI with an immediate presence in Europe.
In combination with AMRI's facilities in the U.S. and Asia, the acquisition enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.
"All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.
Stereochemistry is a science of reflection. Two chemical molecules with the same composition and structure, but with one as the mirror image of the other, can produce wildly varying effects. But University of Utah chemist Matt Sigman has been developing a way to get a better grasp on this tricky field of chemistry.READ MORE